Greater Benefit for Pioglitazone in High-Risk Patients Post Stroke

Share this content:
Greater Benefit for Pioglitazone in High-Risk Patients Post Stroke
Greater Benefit for Pioglitazone in High-Risk Patients Post Stroke

MONDAY, Sept. 18, 2017 (HealthDay News) -- For patients after an ischemic stroke or transient ischemic attack, pioglitazone is associated with greater benefit for those at higher risk for stroke or myocardial infarction (MI), according to a study published online Sept. 18 in JAMA Neurology.

Walter N. Kernan, M.D., from the Yale School of Medicine in New Haven, Conn., and colleagues conducted a secondary analysis of a trial of pioglitazone for secondary prevention among patients with an ischemic stroke or transient ischemic attack and insulin resistance. Patients were stratified for risk of stroke or MI within five years; the efficacy of pioglitazone for preventing stroke or MI was calculated within each stratum.

The researchers found that the five-year risk for stroke or MI was 6.0 percent in the pioglitazone group compared with 7.9 percent in the placebo group, among patients with lower baseline risk (absolute risk difference, −1.9 percent; 95 percent confidence interval, −4.4 to 0.6 percent). The risk was 14.7 and 19.6 for patients at higher risk in the pioglitazone and placebo groups, respectively (absolute risk difference, −4.9 percent; 95 percent confidence interval, −8.6 to 1.2 percent). Similar hazard ratios were seen for patients below or above the median risk (0.77 versus 0.75; P = 0.92).

"After an ischemic stroke or transient ischemic attack, patients at higher risk for stroke or MI derive a greater absolute benefit from pioglitazone compared with patients at lower risk," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Older Adults Less Likely to Have Provider-Ordered Flu Testing

Older Adults Less Likely to Have Provider-Ordered Flu ...

Presence of influenza-like illness, younger age independently predict provider-ordered testing

Nutrients in Child's First 1,000 Days Key for Neurodevelopment

Nutrients in Child's First 1,000 Days Key for ...

Nutrition in prenatal period and first two years of life affects prenatal nutrient delivery, child development

In-Office Angiolytic Laser Effective for Vocal Polyps

In-Office Angiolytic Laser Effective for Vocal Polyps

Fewer adverse events for patients treated with laser plus concurrent polypectomy than laser alone

is free, fast, and customized just for you!

Already a member?

Sign In Now »